


PHARMACEUTICAL 2023

ELI LILLY & Co Rank 249 of 446









ELI LILLY & Co Rank 249 of 446



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 14% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	18,034,500
Cost of Goods Sold	6,629,800
Intangible Assets	11,279,600
Liabilities, Current	17,138,200
Liabilities, Non-Current	21,576,200
Other Assets	10,031,700
Other Compr. Net Income	498,500
Other Expenses	2,035,600
Other Liabilities	0
Other Net Income	0
Other Revenues	28,541,400
Property and Equipment	10,144,000
Research and Development	7,190,800
Selling, General and Administrative Expense	6,440,400

Output Variable	Value in 1000 USD
Assets	49,489,800
Liabilities	38,714,400
Expenses	22,296,600
Revenues	28,541,400
Stockholders Equity	10,775,400
Net Income	6,244,800
Comprehensive Net Income	6,494,050
Economic Capital Ratio	57%

